When ChrysCapital, one of India’s oldest and largest homegrown private equity firms, finalized its 1,446 crore rupee acquisition of a controlling 70.68 percent stake in Novartis India Limited in July 2026, the transaction represented more than just another deal it marked a symbolic culmination of the firm’s 27-year journey in Indian pharmaceuticals. Founded in 1999…
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
